Raymond James analyst issues MARKET PERFORM recommendation for NKTR on October 8, 2026 08:07PM ET. NKTR was trading at $40.8 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 22 - Buy, 6 - Hold, 5 - Sell recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when...
VCI Global Limited (VCIG) confirmed earnings release on October 09, 2026, Before the market for the...
AngioDynamics, Inc. (ANGO) confirmed earnings release on October 08, 2026, Before the market for the quarter...
Comtech Telecommunications Corp. (CMTL) confirmed earnings release on October 08, 2026, Before the market for the...
Toro Corp. (TORO) confirmed earnings release on October 08, 2026, Before the market for the quarter...
from Seaport Global issued a price target of $422.00 for DAVE on 2026-10-08 13:59:09.The adjusted price target was set to $422.00.At the time of the announcement, DAVE was trading at...
from Oppenheimer issued a price target of $115.00 for GHM on 2026-10-08 11:44:40.The adjusted price target was set to $115.00.At the time of the announcement, GHM was trading at $84.34.The...
Kambiz Yazdi from Jefferies issued a price target of $39.00 for ARQT on 2026-10-08 08:23:00.The adjusted price target was set to $39.00.At the time of the announcement, ARQT was trading...
Adam Kroll from Piper Sandler issued a price target of $20.00 for LCNB on 2026-10-08 07:52:00.The adjusted price target was set to $20.00.At the time of the announcement, LCNB was...
Brad Zelnick from Deutsche Bank issued a price target of $35.00 for VIA on 2026-10-07 13:02:40.The adjusted price target was set to $35.00.At the time of the announcement, VIA was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
